Publications
February 8, 2023
New from ADAI: Community Implementation of Contingency Management to Address Stimulant Use (Hartzler, 2023)
A new publication by ADAI Research Associate Professor Bryan Hartzler, PhD and colleagues reports outcomes of an interagency partnership among the Northwest ATTC, Oregon Health Authority, and Oregon Recovery and Treatment Centers, LLC. This partnership involved an intensive technical assistance project in which opioid treatment programs successfully implemented customized contingency management programming to increase stimulant abstinence…
February 6, 2023
New: How Should Policymakers Regulate the THC Content of Cannabis Products? (Opinion piece in Addiction)
Since the sale of cannabis to adults was first legalized in Colorado and Washington State in 2012, the THC content of cannabis flower has increased and so have sales of high-potency cannabis vapes, extracts, and concentrates. Increased use of higher THC cannabis products can lead to increased cannabis-related harms, including accidents, adverse psychological reactions, psychotic…
February 3, 2023
New Research: “Like it was just everyday business”: Experiences of Pharmacy Customers Requesting Naloxone or Syringes
As rates of overdoses involving opioids continue to rise in the U.S., community pharmacies are increasingly being seen as a way to provide easier and expanded access to harm reduction supplies like naloxone and non-prescription syringes (NPS). This article, co-authored by ADAI Research Associate Professor Anthony S. Floyd, PhD, looks at what customers thought of…
January 30, 2023
High THC Policy | Final Report: Exploring Policy Solutions: Report to the WA Legislature
To address this emerging public safety challenge of increasingly available high-THC products (e.g. dabs, wax, concentrates), the WA State Health Care Authority was directed by ESSB 5092 (2021) to contract with the University of Washington’s Addictions, Drug & Alcohol Institute (ADAI) to identify areas of common ground and consensus, and develop recommendations for state policies related to cannabis concentration…
November 30, 2022
ADAI CERP Report to Legislature Details Public Health Risks for High-THC Cannabis
In early fall, ADAI Acting Associate Professor Beatriz Carlini, PhD, MPH and her team at the Cannabis Education & Research Program (CERP) published and delivered a report to the Washington State legislature that addresses the public health challenges of cannabis products with high concentrations of THC, the psychoactive ingredient in cannabis that causes a “high.”…
November 23, 2022
New from ADAI: Provider Perspectives on Medication Treatment for OUD in Adolescents
Despite recent surges in adolescent opioid use disorder (OUD), teens are less likely to enter treatment compared to adults, and are rarely in treatment settings that offer evidence-based medication treatment (methadone, buprenorphine, and naltrexone). Buprenorphine is the only medication approved for people under 18 (aged 16 and older) and methadone requires written parental consent for…
November 8, 2022
New ADAI Report: Overdose Deaths Involving Prescription Opioids in WA, 2010-2021
This new report by Caleb Banta-Green, PhD, MPH, MSW and Jason Williams, PhD of the ADAI Center for Community-Engaged Drug Education, Epidemiology & Research (CEDEER) examines key indicators related to pharmaceutical opioids including sales data and overdose death rates. Key Points Prescription opioid overdose deaths declined from their peak in 2006, but are higher than…
November 7, 2022
New Research from ADAI: Opioid Safety Intervention for Community Pharmacists
ADAI Research Associate Professor Anthony Floyd, PhD has a new paper out describing an assessment of community pharmacists’ readiness to implement an educational program that aims to boost their knowledge and confidence when it comes to providing opioid safety and harm reduction services to patients and customers. What is the context for this study? Community…
October 18, 2022
Virtual Training More Cost-Effective Than In-Person Training for Contingency Management
Contingency management (CM) is an evidence-based practice that uses behavioral reinforcement, like rewards, to shape client behavior toward a treatment goal, such as attending counseling sessions or abstinence. The intervention has been studied extensively in addiction treatment settings for half a century and found reliably effective in treatment of both opioid use disorder and methamphetamine…
August 2, 2022
Cannabis-Related Calls to the WA Poison Center, 2017-2021
The Washington Poison Center (WPC) receives calls for help about people who used a substance and experienced negative reactions. An increase in poison center calls for cannabis consumption has been documented in legalized states since 2014, including Washington. Given this increase and the diversification of legalized cannabis products, poison centers began collecting more information on…
Previous page Next page
